Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To study the effect of co-injecting unlabelled hypericin (Hyp) on biodistribution, necrosis uptake and tumour retention of iodine-123 or iodine-131 labelled hypericin ((123/131)I-Hyp), a necrosis avid agent for an anticancer radiotherapy.
Methods: (123/131)I-Hyp was prepared with Iodogen as oxidant and formulated in 0.6 μg/kg no-carrier-added (NCA) or 0.25 mg/kg unlabelled Hyp carrier-added (CA) forms using dimethyl sulfoxide/polyethylene glycol-400/propylene glycol/water (25/25/25/25% v/v/v/v), as solvent mixture. Comparisons on biodistribution and necrosis uptake of NCA and CA(123)I-Hyp were conducted on rats (n=24) of reperfused liver infarction (RPLI) in 48h p.i. Tumour retention of CA(131)I-Hyp was assessed in severe combined immunodeficiency (SCID) mice with fibrosarcoma (RIF-1) tumours (n=25) over 40 days. To cause intratumour necrosis, mice were pre-treated with a vascular disrupting agent CA4P at 10mg/kg. Tissue-gamma counting (TGC), autoradiography and histology were performed.
Results: TGC revealed no significant difference in organ biodistribution between RPLI-rats injected with NCA and CA(123)I-Hyp, except in intestines, liver, lungs and stomach (P<0.05). Both preparations showed hepatobiliary excretion since intestines and faeces retained the most radioactivity. NCA and CA(123)I-Hyp exhibited high avidity and selectivity for hepatic infarction. From the day after injection onward, CA(123)I-Hyp showed greater target accumulation (7-11%ID/g) than (123)I-Hyp alone (~4%ID/g; P<0.05). In RIF-1-SCID mice receiving CA(131)I-Hyp, prolonged high retention in tumour necrosis was detected over 40 days p. i. TGC findings were confirmed by histological and autoradiographic analysis.
Conclusions: The study demonstrated the co-injection of unlabelled Hyp affected necrosis uptake but almost no biodistribution of radioiodinated Hyp. Long-term high retention into tumour necrosis characterizes the carrier-added (131)I-Hyp.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/18715206113136660360 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted oral delivery of microencapsulated TNF-α siRNA in an experimental model of colitis.
Drug Deliv Transl Res
August 2025
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, TAI-IT UFR Santé, 19 rue Ambroise Paré, Besançon, F-25000, France.
Inflammatory bowel diseases (IBD) affect millions of people worldwide. The use of anti-TNF-α for the treatment of moderate-to-severe IBD faces primary non-response, loss of response during treatment or intolerance issues. As an alternative, a strategy consisting of oral administration of TNF-α siRNA was evaluated in the present study for the local treatment of IBD.
View Article and Find Full Text PDFHDL and LDL-bioinspired nanocarriers in acellular targeted delivery of Icariin for cardiac repair post myocardial infarction.
Eur J Pharm Biopharm
September 2025
Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. Electronic address:
Myocardial infarction (MI) is a major ischemic heart condition that leads to the loss of billions of cardiomyocytes, triggering adverse ventricular remodeling and fibrotic tissue formation, which can ultimately result in heart failure. Current treatments fail to address cardiomyocyte loss, prompting interest in cardiac regeneration strategies. Although cell-based therapies have gained attention, they face limitations such as poor cell survival and engraftment.
View Article and Find Full Text PDFDevelopment of an mRNA vaccine encoding IHNV glycoprotein protects rainbow trout (Oncorhynchus mykiss) from infection.
NPJ Vaccines
July 2025
State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, East China University of Science and Technology, Shanghai, China.
mRNA vaccines have demonstrated significant potential in preventing human diseases and controlling livestock infections. However, the application of mRNA vaccines in aquaculture, especially on fish, remains limited. Infectious hematopoietic necrosis virus (IHNV) is an RNA virus that mainly affects rainbow trout (Oncorhynchus mykiss), leading to high mortality rates.
View Article and Find Full Text PDFTransabdominal ultrasound guided AAV9-GFP delivery in fetal pigs: a translational and minimally invasive model for in utero fetal gene therapy.
Gene Ther
July 2025
Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.
In utero fetal gene therapy (IUFGT) has the potential to correct severe monogenic disorders before irreversible damage occurs. Despite promising results in small and large animal models, its translation to clinical practice remains limited by technical challenges, safety concerns, and the lack of standardized protocols in relevant disease models species. We established and validated a minimally invasive, ultrasound-guided approach for systemic gene delivery in fetal pigs using a self-complementary AAV9 vector encoding GFP under a CAG promoter.
View Article and Find Full Text PDFPlatelet Membrane-Coated Poly (Lactic-Co-Glycolic Acid) Nanoparticles as a Targeting Drug Delivery System for Multidrug-Resistant Breast Cancer.
Int J Nanomedicine
July 2025
College of Pharmacy, Chungnam National University, Daejeon, 31434, Republic of Korea.
Introduction: Paclitaxel (PTX), widely used chemotherapeutic agent, is limited by poor solubility, P-glycoprotein (P-gp) mediated efflux, and non-specific toxicity. To overcome these challenges, we developed a triple-functionalized nanocarrier system incorporating poly(lactide-co-glycolide) (PLGA)-based nanoparticles (PNs), D-α-tocopheryl polyethylene glycol succinate (TPGS) for P-gp inhibition, and platelet membrane (PM) coating for targeted tumor delivery.
Methods: The PM-coated TPGS-modified PNs with PTX (PTPNs) was characterized by particle size analysis, transmission electron microscopy (TEM), and protein assay to confirm PM coating.